Puzo Michael J Takes Position in Roche Holding AG $RHHBY

Puzo Michael J bought a new stake in Roche Holding AG (OTCMKTS:RHHBY) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 23,940 shares of the company’s stock, valued at approximately $1,229,000.

Several other large investors have also recently added to or reduced their stakes in the business. Confluence Investment Management LLC boosted its stake in Roche by 1.2% in the 2nd quarter. Confluence Investment Management LLC now owns 20,925 shares of the company’s stock worth $1,074,000 after buying an additional 258 shares during the last quarter. Oakworth Capital Inc. increased its stake in shares of Roche by 20.8% during the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after acquiring an additional 285 shares during the last quarter. Enterprise Financial Services Corp increased its stake in shares of Roche by 6.6% during the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock valued at $277,000 after acquiring an additional 345 shares during the last quarter. Archer Investment Corp lifted its holdings in shares of Roche by 7.7% during the 1st quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock worth $278,000 after acquiring an additional 398 shares during the period. Finally, Diversified Trust Co lifted its holdings in shares of Roche by 0.8% during the 1st quarter. Diversified Trust Co now owns 59,375 shares of the company’s stock worth $2,907,000 after acquiring an additional 448 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Morgan Stanley raised shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price on the stock in a research report on Friday, August 7th. Zacks Research downgraded shares of Roche from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $60.00.

Roche Trading Up 5.2%

Shares of OTCMKTS:RHHBY opened at $58.40 on Thursday. The stock has a 50-day simple moving average of $53.06 and a 200-day simple moving average of $52.92. Roche Holding AG has a 1 year low of $39.50 and a 1 year high of $60.85. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann?La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.